This artificial intelligence (AI) Industry Insight focuses on the latest updates on the use of AI in the medical communications and healthcare industries. Here are three articles covering Novo Nordisk’s new AI research hub, the potential biases of generative AI in academic writing, and a new 2024 AI partnership between Amgen and NVIDIA.
Novo Nordisk has announced that it plans to open a new AI-based research facility in King’s Cross Knowledge Quarter, London. They aim to move into this space in the first quarter of this year, with the focus being on advancing drug discovery operations in London. They will join other leading companies, including GSK and AstraZeneca. This comes on the back of a recent press release from Valo Health and Novo Nordisk last September that announced their collaboration to discover and develop novel treatments for cardiometabolic diseases using human data and AI.
This research articlehas found that incorporating generative AI in the process of writing research manuscripts can result in a new type of context-induced algorithmic bias. These biases in AI systems are insidious and often hard to detect. This paper focuses on context-induced bias, which occurs when the output is adjusted based on the linguistic patterns and data-driven stereotypes that it has learned from its dataset.
The authors detail several detrimental effects this could have on academia, knowledge production, and research communication. These will particularly affect underrepresented groups in research as hallucinatory behaviour can influence researchers to follow biased directions as large language models reaffirm incorrect statements with hallucinated information. Furthermore, particular prompts and queries can influence large language models to produce biased information. All of these are detrimental to any of the gains made that aim to employ under represented groups in research.
NVIDIA is one of the world leaders in AI computing. Amgen will build AI models to analyse one of the world’s largest human datasets using NVIDIA technology to develop a human diversity atlas for drug target and disease-specific biomarker discovery. This will hopefully provide diagnostics for disease progression and regression, with the use of NVIDIA technology to expedite the training of these AI models. This is another of NVIDIA’s health partnerships, with a recent announcement last November that it was partnering with Flywheel.
